TABLE 1.
Abnormal CS (<1.5 logCS)a in Either Eye (n=284) |
Normal CS (≥1.5 logCS) in Both Eyes (n = 1407) |
||||
---|---|---|---|---|---|
Factor | Nc | Valued | Nc | Valued | P Valueb |
Demographics | |||||
Age | 283 | 43 years | 1402 | 43 years | .16 |
Female | 283 | 26% | 1402 | 18% | .001 |
Black | 283 | 46% | 1402 | 35% | .0005 |
HIV infection risk group | 275 | 1385 | <.0001 | ||
MSM only | — | 38% | — | 58% | |
IDU only | — | 14% | — | 9% | |
Both MSM and IDU | — | 6% | — | 4% | |
Heterosexual contact | — | 36% | — | 25% | |
Other | — | 6% | — | 4% | |
AIDS history | |||||
Interval since AIDS diagnosis (median) | 273 | 4.5 years | 1371 | 3.7 years | .006 |
Lymphocytopenia as AIDS-defining illness | 283 | 61% | 1402 | 66% | .11 |
Weight | 261 | 72 kg | 1283 | 75 kg | .0007 |
Immunology/virology | |||||
CD4+ T-lymphocyte count | 282 | 166 cells/μL | 1393 | 194 cells/μL | .02 |
Nadir CD4+ T-lymphocyte count | 273 | 38 cells/μL | 1387 | 44 cells/μL | .28 |
CD8+ T-lymphocyte count | 280 | 731 cells/μL | 1385 | 776 cells/μL | .15 |
HIV RNA blood level | 258 | 3.0 log copies/mL | 1348 | 2.8 log copies/mL | .28 |
Peak HIV RNA blood level | 264 | 5.3 log copies/mL | 1348 | 5.3 log copies/mL | .12 |
Hematology | |||||
Hemoglobin concentration | 283 | 13.3 g/dL | 1397 | 13.8 g/dL | .0004 |
Median hematocrit | 282 | 39.2% | 1399 | 40.4% | .0008 |
Mean corpuscular volume | 282 | 97.2 fL | 1400 | 98.0 fL | .45 |
Platelet count | 281 | 217 × 103 cells/μL | 1390 | 212 × 103 cells/μL | .44 |
Leukocyte count | 283 | 4.5 × 103 cells/μL | 1400 | 4.6 × 103 cells/μL | .51 |
Absolute neutrophil count | 282 | 2.4 × 103 cells/μL | 1394 | 2.3 × 103 cells/μL | .90 |
Comorbidities | |||||
Hypertension | 282 | 26% | 1402 | 20% | .03 |
Diabetes mellitus | 283 | 10% | 1402 | 9% | .71 |
Renal disease | 283 | 5% | 1402 | 7% | .43 |
Cardiovascular diseasee | 199 | 9% | 1103 | 7% | .33 |
Peripheral vascular disease | 198 | 7% | 1097 | 4% | .11 |
Stroke | 198 | 8% | 1093 | 4% | .02 |
Antiretroviral treatment | |||||
Ever on HAART | 225 | 88% | 1172 | 90% | .20 |
Currently on HAART | 282 | 79% | 1402 | 85% | .006 |
Mean Karnofsky score | 283 | 82 | 1401 | 85 | .0002 |
Visual function (better eye) | |||||
Visual acuity (standardized letters) | 283 | 83 | 1402 | 90 | <.0001 |
Goldmann visual field (degrees) | 279 | 730 | 1398 | 756 | <.0001 |
Presence of cotton-wool spots | 283 | 5% | 1401 | 3% | .02 |
AIDS = acquired immunodeficiency syndrome; CS = contrast sensitivity; HAART = highly active antiretroviral therapy; HIV = human immunodeficiency virus; IDU = intravenous drug user; MSM = men who have sex with men.
Corresponds to the lower 2.5th percentile for a normal control population described by Myers and associates.14
Wilcoxon rank sum test for continuous variables; χ2 test for categorical variables.
The number of study participants for whom data were available.
Values other than percentages represent medians unless otherwise stated.
Includes coronary heart disease and peripheral vascular disease.